Stepwise selection of mutation conferring fluroquinolone resistance: multisite MDR-TB cohort study
- 18 February 2021
- journal article
- research article
- Published by Springer Science and Business Media LLC in European Journal of Clinical Microbiology & Infectious Diseases
- Vol. 40 (8), 1767-1771
- https://doi.org/10.1007/s10096-021-04187-5
Abstract
In this study, we demonstrate that fluroquinolone (FQ) is at risk of acquired drug resistance after continuous exposure. The reduced susceptibility is observed in subsequent Mycobacterium tuberculosis isolates from patients without FQ exposure. The stepwise selection of mutation of increasing FQ resistance highlights the urgent need for monitoring FQ resistance in multidrug-resistant tuberculosis patients throughout the entire treatment course.Keywords
This publication has 10 references indexed in Scilit:
- Reduced Susceptibility of Mycobacterium tuberculosis to Bedaquiline During Antituberculosis Treatment and Its Correlation With Clinical Outcomes in ChinaClinical Infectious Diseases, 2020
- Role of low-level quinolone resistance in generating tolerance in Escherichia coli under therapeutic concentrations of ciprofloxacinJournal of Antimicrobial Chemotherapy, 2020
- SpecificgyrAgene mutations correlate with high prevalence of discordant levofloxacin resistance inMycobacterium tuberculosisisolates from Beijing, ChinaPublished by Cold Spring Harbor Laboratory ,2019
- Limited Scope of Shorter Drug Regimen for MDR TB Caused by High Resistance to FluoroquinoloneEmerging Infectious Diseases, 2019
- Clinical outcome of multidrug-resistant tuberculosis patients receiving standardized second-line treatment regimen in ChinaJournal of Infection, 2018
- Double mutation in DNA gyrase confers moxifloxacin resistance and decreased fitness of Mycobacterium smegmatisJournal of Antimicrobial Chemotherapy, 2017
- Genotyping and Prevalence of Pyrazinamide- and Moxifloxacin-Resistant Tuberculosis in China, 2000 to 2010Antimicrobial Agents and Chemotherapy, 2017
- Mutations in gyrA and gyrB among Fluoroquinolone- and Multidrug-Resistant Mycobacterium tuberculosis IsolatesAntimicrobial Agents and Chemotherapy, 2016
- Extensive Drug Resistance Acquired During Treatment of Multidrug-Resistant TuberculosisClinical Infectious Diseases, 2014
- Evaluation of moxifloxacin for the treatment of tuberculosis: 3 years of experienceEuropean Respiratory Journal, 2011